Top 4 questions about SICKLEDEX
Streck listened to customers and has made improvements to the Instructions for Use (IFU) for SICKLEDEX®, improving the customer experience by enablin…
Read More CD-Chex Plus®
CD-Chex Plus is a positive procedural control for immunophenotyping by flow cytometry on BD Biosciences and Beckman Coulter flow cytometry systems. Assayed for 30 parameters including T-lymphocytes, B-lymphocytes, granulocytes, NK cells and a normal level of CD34+ cells. The whole blood control is available in two clinically relevant levels of CD4+ cells.
Product Description
CD-Chex Plus is a positive procedural control for monitoring immunophenotyping by flow cytometry. It provides 30 assayed parameters including T-lymphocytes, B-lymphocytes, granulocytes, monocytes and NK cells. It is available in two clinically relevant levels of CD4+ cells and is assayed for a normal level of CD34+ cells. Designed to mimic a patient sample, CD-Chex Plus is manufactured from normal human peripheral blood leukocytes and erythrocytes. The whole blood control offers 30-day open-vial stability, eliminating the need to track thermal openings. Its long shelf life reduces the number of shipments, associated costs and time spent performing lot-to-lot correlation. CD-Chex Plus and CD-Chex Plus CD4 Low are available in plastic vials with pierceable caps for use with automated flow cytometry sample preparation instruments, reducing errors and improving laboratory workflow.
Features
- Assayed for 30 parameters
- Available in two clinically relevant levels of CD4+ cells
- Assayed for a normal level of CD34+ cells
- Compatible with BD Biosciences and Beckman Coulter flow cytometry systems
- 30-day open-vial stability
- 90-day closed-vial stability
Benefits
- Helps laboratory meet CLIA guidelines
- Established assay ranges provide less room for error
- Reduces the need for labs to hold and validate patient samples for use as a control
- Fewer lot-to-lot correlations saves time and resources
- Long shelf life reduces the number of shipments and associated costs
- Access to STATS®, a free interlaboratory quality control program with peer group data comparison and online submission
Resources
Instructions (IFU)
Assays
Product Information
Looking for an older document? Click here for archived assays and certificates.
Quality Pillars for Building Measurement Assurance in Flow Cytometry
The webinar provides updates on the current best quality practices in flow cytometry and case studies for assay, reagent and instrument monitoring.
Ordering Information
| Description | Catalog Number |
|---|---|
| 2 x 3.0 mL CD-Chex Plus, Plastic | 213365 |
| 2 x 3.0 mL CD-Chex Plus CD4 Low, Plastic | 213366 |
| 2 x 3.0 mL CD-Chex Plus CD4 Low, Normal, Plastic | 213391 |
| 4 x 3.0 mL CD-Chex Plus CD4 Low, Normal, Plastic | 213369 |
| 5 x 3.0 mL CD-Chex Plus, Plastic | 213367 |
| 5 x 3.0 mL CD-Chex Plus CD4 Low, Plastic | 213368 |
| 10 x 3.0 mL CD-Chex Plus CD4 Low, Normal, Plastic | 213370 |
Order CD-Chex Plus today
International customers find a distributor
Flow Cytometry Products
Based on Streck’s proprietary cell-stabilization technology, we offer a comprehensive line of positive procedural controls and cellular stabilization products for immunophenotyping by flow cytometry. Our unique quality controls provide assay values for both normal and abnormal leukocyte populations and reference values for both intracellular and surface markers. Our cellular stabilization products are designed to preserve samples for extended periods while easing handling concerns and allowing for room temperature storage, cold-chain free shipping and batch processing.
The latest from the blog
Quality Control
Quality Control
Male infertility causes and testing
Many couples face issues with fertility, or the ability to have children. If a pregnancy is not achieved after 12 months of having unprotected sex, th…
Read More 
Quality Control
Understanding diabetes A1c tests
According to the World Health Organization (WHO), the number of people worldwide with diabetes rose from 108 million in 1980 (4.7% of the adult popula…
Read More